U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H14N5O4P
Molecular Weight 287.2123
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TENOFOVIR ANHYDROUS

SMILES

C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O

InChI

InChIKey=SGOIRFVFHAKUTI-ZCFIWIBFSA-N
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1

HIDE SMILES / InChI

Molecular Formula C9H14N5O4P
Molecular Weight 287.2123
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA known as tenofovir) is an antiviral drug. Diphosphate of PMPA acts as a selective inhibitor of the HIV-1 reverse transcriptase. Tenofovir disoproxil was approved for clinical use for the treatment of HIV infection (AIDS) and chronic HBV infection.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
58.0 µM [Kd]
3.3 nM [EC50]
3.5 nM [EC50]
0.49 µM [EC50]
0.3 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VIREAD
Primary
VIREAD
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
209.6 ng/mL
150 mg single, oral
TENOFOVIR plasma
Homo sapiens
456.7 ng/mL
300 mg single, oral
TENOFOVIR plasma
Homo sapiens
448.5 ng/mL
300 mg single, oral
TENOFOVIR plasma
Homo sapiens
989.8 ng/mL
600 mg single, oral
TENOFOVIR plasma
Homo sapiens
523.4 ng/mL
300 mg 1 times / day multiple, oral
TENOFOVIR plasma
Homo sapiens
0.03 μg/mL
25 mg 1 times / day multiple, oral
TENOFOVIR plasma
Homo sapiens
326 ng/mL
245 mg 1 times / day multiple, oral
TENOFOVIR serum
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
2079.1 ng × h/mL
150 mg single, oral
TENOFOVIR plasma
Homo sapiens
3006.1 ng × h/mL
300 mg single, oral
TENOFOVIR plasma
Homo sapiens
3408.2 ng × h/mL
300 mg single, oral
TENOFOVIR plasma
Homo sapiens
6373.9 ng × h/mL
600 mg single, oral
TENOFOVIR plasma
Homo sapiens
4476.7 ng × h/mL
300 mg 1 times / day multiple, oral
TENOFOVIR plasma
Homo sapiens
0.4 μg × h/mL
25 mg 1 times / day multiple, oral
TENOFOVIR plasma
Homo sapiens
3324 ng × h/mL
245 mg 1 times / day multiple, oral
TENOFOVIR serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
18.54 h
150 mg single, oral
TENOFOVIR plasma
Homo sapiens
17.56 h
300 mg single, oral
TENOFOVIR plasma
Homo sapiens
16.86 h
300 mg single, oral
TENOFOVIR plasma
Homo sapiens
18.92 h
600 mg single, oral
TENOFOVIR plasma
Homo sapiens
17.12 h
300 mg 1 times / day multiple, oral
TENOFOVIR plasma
Homo sapiens
18 h
245 mg 1 times / day multiple, oral
TENOFOVIR serum
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
99.3%
TENOFOVIR plasma
Homo sapiens
99.3%
245 mg 1 times / day multiple, oral
TENOFOVIR serum
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
For hepatitis B - 5-100mg tablet
Route of Administration: Oral
In Vitro Use Guide
CMX-157 was active against all major subtypes of HIV-1 and HIV-2 in fresh human peripheral blood mononuclear cells (PBMCs) and against all HIV-1 strains evaluated in monocyte-derived macrophages, with 50% effective concentrations (EC(50)s) ranging between 0.20 and 7.2 nM.
Substance Class Chemical
Record UNII
W4HFE001U5
Record Status Validated (UNII)
Record Version